Fondazione IRCCS Istituto Neurologico Carlo Besta, Department of Clinical Neurosciences, Parkinson and Movement Disorders Unit, Milan, Italy.
Department of Medical Sciences and Advanced Surgery, University of Campania, Naples, Italy.
Mov Disord. 2020 Aug;35(8):1287-1292. doi: 10.1002/mds.28170. Epub 2020 Jun 11.
The impact of coronavirus disease 2019 (COVID-19) on clinical features of Parkinson's disease (PD) has been poorly characterized so far. Of 141 PD patients resident in Lombardy, we found 12 COVID-19 cases (8.5%), whose mean age and disease duration (65.5 and 6.3 years, respectively) were similar to controls. Changes in clinical features in the period January 2020 to April 2020 were compared with those of 36 PD controls matched for sex, age, and disease duration using the clinical impression of severity index for PD, the Movement Disorders Society Unified PD Rating Scale Parts II and IV, and the nonmotor symptoms scale. Motor and nonmotor symptoms significantly worsened in the COVID-19 group, requiring therapy adjustment in one third of cases. Clinical deterioration was explained by both infection-related mechanisms and impaired pharmacokinetics of dopaminergic therapy. Urinary issues and fatigue were the most prominent nonmotor issues. Cognitive functions were marginally involved, whereas none experienced autonomic failure. © 2020 International Parkinson and Movement Disorder Society.
到目前为止，COVID-19（新冠肺炎）对帕金森病（PD）临床特征的影响还没有很好的描述。在居住在伦巴第的 141 名 PD 患者中，我们发现了 12 例 COVID-19 病例（8.5%），其平均年龄和病程（分别为 65.5 和 6.3 岁）与对照组相似。使用 PD 严重程度临床印象指数、运动障碍协会统一 PD 评定量表第二部分和第四部分以及非运动症状量表，比较了 2020 年 1 月至 2020 年 4 月期间 COVID-19 组与 36 名性别、年龄和病程匹配的 PD 对照组的临床特征变化。在 COVID-19 组中，运动和非运动症状显著恶化，三分之一的病例需要调整治疗。临床恶化的原因既有感染相关机制，也有多巴胺能治疗药代动力学受损。尿失禁和疲劳是最突出的非运动问题。认知功能略有受影响，而无一例自主神经衰竭。© 2020 国际帕金森病和运动障碍协会。
